TNYA$0.3675+1.80%
Tenaya Therapeutics, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$82.4M
Float & O/S:174.04M / 224.23M
Inst Own:24.0%
DilutionScan read 36 of Tenaya Therapeutics, Inc.'s SEC filings and found 5 warrant series, 1 ATM program, 2 shelf registrations and 1 completed offering on file for TNYA. The latest dilution event on file is ATM sales on Dec 31, 2025. Analysis updated Oct 6, 2026.
Signal8 Summary
TNYA
Tight cash runway and high burn
Snapshot
Tenaya Therapeutics is a clinical-stage biotech burning cash with a tight runway. It generated no revenue in FY 2025 and spent roughly $69M in free cash flow.
What's Happening Right Now
- : Appointed Eric Hyllengren as Chief Financial Officer effective July 2026 to replace the retiring Hiro Higa.
- : Interim data from the MyPEAK-1 trial showed TN-201 gene therapy resulted in cardiac remodeling and symptom reductions for patients with MYBPC3-associated HCM.
- : Interim data from the RIDGE-1 trial showed TN-401 gene therapy demonstrated a 64% mean reduction in arrhythmia burden for patients with PKP2-associated ARVC.
